🇺🇸 FDA
Patent

US 9181222

Protein kinase C inhibitors and uses thereof

granted A61KA61K31/506A61P

Quick answer

US patent 9181222 (Protein kinase C inhibitors and uses thereof) held by Rigel Pharmaceuticals, Inc. expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Nov 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/506, A61P, A61P1/00, A61P1/04